### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name	of entity
1 Tullic	OI CIILILY

Chant West Holdings Limited (formerly Enzumo Limited)

ABN

62 119 383 578

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- +Class of +securities issued or to be issued
- 1. Fully paid ordinary shares (**Shares**)
- 2. An Option
- 3. Performance Rights
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 1. 4,000,000 Shares
- 2. An Option exercisable over 13,300,000 Shares
- 3. 4,000,000 Performance Rights

<sup>+</sup> See chapter 19 for defined terms.

- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- 1. Fully paid ordinary shares
- 2. An Option over 13,300,00 Shares at an exercise price of \$0.06 per Share expiring 30/06/18
- 3. Performance Rights will vest at a rate of 1,000,000 shares over the following four tranches: (1) 1/3/2018 to 29/2/2020, (2) 1/3/2019 to 28/2/2021, (3) 1/3/2020 to 28/2/2020, and (4) 1/3/2020 28/2/2022. Vesting of the Performance Rights are also subject to the performance conditions of VWAP reaching 10 cents or more and 14 cents or more for Tranches 1 and 2 respectively, and EBITDA reaching \$2 million or more and \$3.5 million or more for Tranches 3 and 4 respectively.
- Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- 1. Yes, the Shares rank equally in all respects from the date of issue with the existing quoted fully paid ordinary shares of the Company.
- 2. No. The Option is an unquoted security. If the Option is exercised, shares issued will rank equally in all respects from the date of issue with the existing quoted fully paid ordinary shares of the Company.
- 3. No. Performance Rights do not rank equally with existing fully paid ordinary shares from the date of issue and do not participate in any dividend, distribution or interest payment.

Shares issued on the conversion of Performance Rights will rank equally in all respects from the date of issue with the existing quoted fully paid ordinary shares of the Company.

		2. \$10.00 for the Option
		3. Nil consideration for the Performance Rights
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly	4,000,000 Shares issued to directors in lieu of cash bonus.
	identify those assets)	2. An Option over 13,300,000 Shares issued to the nominee of a director to coincide with his commencement as CEO.
		3. 4,000,000 Performance Rights issued under the Employee Performance Rights Plan.
		The above security issues were approved by Shareholders at the 2017 Annual General Meeting.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	28 November 2017
6с	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
_		Tarist.
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil

1. \$0.06 per Share

Issue price or consideration

5

<sup>+</sup> See chapter 19 for defined terms.

6f Number of \*securities issued under an exception in rule 7.2

8,000,001

6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the \*issue date and both values. Include the source of the VWAP calculation.

N/A

6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Listing Rule 7.1 –16,193,401 Listing Rule 7.1A – 10,795,601

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

20 December 2017

8 Number and +class of all +securities quoted on ASX (*including* the +securities in section 2 if applicable)

Number	<sup>+</sup> Class
Before issue of Shares	Ordinary Shares
=103,956,012 Issue of Shares	
= 4,000,000	Ordinary Shares
After issue of Shares = 107,956,012	Ordinary Shares

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
1,800,000	Class A Performance
	Shares
1,800,000	Class B Performance
	Shares
1,800,000	Class C Performance
	Shares
Other unquoted securities	

200,000	Options over ordinary shares with an exercise price of \$0.30 expiring 23/2/2018
1,950,000	Options over ordinary shares with an exercise price of \$0.30 expiring 30/4/2018
1	Option over 13,300,000 ordinary shares with an exercise price of \$0.06 per share expiring 30/6/2018
1,000,000	Options over ordinary shares with an exercise price of \$0.30 expiring 22/7/2018
1,500,000	Options over ordinary shares with an exercise price of \$0.375 expiring 17/5/2019
4,000,000	Performance Rights

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Company does not currently have a dividend policy.

### Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A

<sup>+</sup> See chapter 19 for defined terms.

14	*Class of *securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their	N/A
	entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if	N/A
	applicable)	
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
	TT 1 % 1 11 11 4	DY/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
22	<sup>+</sup> Issue date	N/A

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities Type of \*securities 34 (tick one) <sup>+</sup>Securities described in Part 1: Ordinary Shares only. (a) (b) All other \*securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities Er

#### A

Entities that have ticked box 34(a)			
Additional securities forming a new class of securities			
Tick to docume	indicate you are providing the information or onts		
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over		
37	A copy of any trust deed for the additional *securities		
Entities that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought N/A		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought N/A		

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	N/A	
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	N/A	N/A

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 

  †securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 20 December 2017

Company Secretary

Print name: Cameron Stone

### **Appendix 3B – Annexure 1**

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	95,458,927	
Add the following:		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	103,956,012	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	4,000,000	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period	Nil	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid  +ordinary securities cancelled during that  12 month period	Nil	
"A"	107,956,012	
Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	

<sup>+</sup> See chapter 19 for defined terms.

<b>Multiply</b> "A" by 0.15	16,193,401	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Nil	
Under an exception in rule 7.2		
Under rule 7.1A		
With security holder approval under rule 7.1 or rule 7.4		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	-	
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	-	
"A" x 0.15	16,193,401	
Note: number must be same as shown in Step 2		
Subtract "C"	-	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	16,193,401	
	[Note: this is the remaining placement capacity under rule 7.1]	

### Part 2

	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"  Note: number must be same as shown in Step 1 of Part 1	107, 956 012	
Step 2: Calculate 10% of "A"		
"D"	0.10  Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	10,795,601	
7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
or agreed to be issued in that 12 month	Nil	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	10,795,601	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	10,795,601	
	Note: this is the remaining placement capacity under rule 7.1A	